Atani’s focus is on delivering much needed novel cancer therapies to the Japanese market. With $8.6 billion USD in sales, Cancer ranks number two in the Japanese pharmaceutical market and is growing at the highest rate. Atani seeks to build a broad and balanced portfolio of oncology and cancer supportive care products to meet this growing need. There is a wealth of product opportunities from European and American innovators, and our product strategy is to identify such cancer drugs for licensing into Japan, complete the clinical development of these products, and successfully commercialize them so that we can help improve outcomes for cancer patients in Japan.

Products in Development

Lobaplatin